{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T15:03:54Z","timestamp":1794409434469,"version":"4.9.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1038\/s41401-021-00703-7","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T14:03:11Z","timestamp":1625493791000},"page":"2016-2032","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Lp-PLA2 inhibition prevents Ang II-induced cardiac inflammation and fibrosis by blocking macrophage NLRP3 inflammasome activation"],"prefix":"10.1038","volume":"42","author":[{"given":"Si-lin","family":"Lv","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-fan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-qiang","family":"Gan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tie-gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-fang","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ri-xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"703_CR1","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.pcad.2006.02.001","volume":"48","author":"AH Gradman","year":"2006","unstructured":"Gradman AH, Alfayoumi F. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease. Prog Cardiovasc Dis. 2006;48:326\u201341.","journal-title":"Prog Cardiovasc Dis"},{"key":"703_CR2","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.trsl.2019.03.001","volume":"209","author":"S Park","year":"2019","unstructured":"Park S, Nguyen NB, Pezhouman A, Ardehali R. Cardiac fibrosis: potential therapeutic targets. Transl Res. 2019;209:121\u201337.","journal-title":"Transl Res"},{"key":"703_CR3","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.116.303697","volume":"116","author":"WG McMaster","year":"2015","unstructured":"McMaster WG, Kirabo A, Madhur MS, Harrison DG. Inflammation, immunity, and hypertensive end-organ damage. Circ Res. 2015;116:1022\u201333.","journal-title":"Circ Res"},{"key":"703_CR4","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1111\/j.1440-1681.2003.03942.x","volume":"30","author":"YC Zhu","year":"2003","unstructured":"Zhu YC, Zhu YZ, Lu N, Wang MJ, Wang YX, Yao T. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and cardiac remodelling. Clin Exp Pharmacol Physiol. 2003;30:911\u20138.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"703_CR5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3389\/fcvm.2019.00101","volume":"6","author":"SA O\u2019Rourke","year":"2019","unstructured":"O\u2019Rourke SA, Dunne A, Monaghan MG. The role of macrophages in the infarcted myocardium: orchestrators of ECM remodeling. Front Cardiovasc Med. 2019;6:101.","journal-title":"Front Cardiovasc Med"},{"key":"703_CR6","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1161\/ATVBAHA.112.248732","volume":"32","author":"M Yang","year":"2012","unstructured":"Yang M, Zheng J, Miao Y, Wang Y, Cui W, Guo J, et al. Serum-glucocorticoid regulated kinase 1 regulates alternatively activated macrophage polarization contributing to angiotensin II-induced inflammation and cardiac fibrosis. Arterioscler Thromb Vasc Biol. 2012;32:1675\u201386.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"703_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2741\/3923","volume":"17","author":"L Jia","year":"2012","unstructured":"Jia L, Li Y, Xiao C, Du J. Angiotensin II induces inflammation leading to cardiac remodeling. Front Biosci (Landmark Ed). 2012;17:221\u201331.","journal-title":"Front Biosci (Landmark Ed)"},{"key":"703_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.immuni.2013.08.037","volume":"39","author":"H Wen","year":"2013","unstructured":"Wen H, Miao EA, Ting JP. Mechanisms of NOD-like receptor-associated inflammasome activation. Immunity. 2013;39:432\u201341.","journal-title":"Immunity"},{"key":"703_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","volume":"13","author":"E Latz","year":"2013","unstructured":"Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol. 2013;13:397\u2013411.","journal-title":"Nat Rev Immunol"},{"key":"703_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00395-017-0663-9","volume":"113","author":"D Liu","year":"2018","unstructured":"Liu D, Zeng X, Li X, Mehta JL, Wang X. Role of NLRP3 inflammasome in the pathogenesis of cardiovascular diseases. Basic Res Cardiol. 2018;113:5.","journal-title":"Basic Res Cardiol"},{"key":"703_CR11","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1021\/cr200085w","volume":"111","author":"EA Dennis","year":"2011","unstructured":"Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011;111:6130\u201385.","journal-title":"Chem Rev"},{"key":"703_CR12","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.plipres.2010.12.001","volume":"50","author":"M Murakami","year":"2011","unstructured":"Murakami M, Taketomi Y, Miki Y, Sato H, Hirabayashi T, Yamamoto K. Recent progress in phospholipase A(2) research: from cells to animals to humans. Prog Lipid Res. 2011;50:152\u201392.","journal-title":"Prog Lipid Res"},{"key":"703_CR13","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.bbalip.2018.08.009","volume":"1864","author":"A Nikolaou","year":"2019","unstructured":"Nikolaou A, Kokotou MG, Vasilakaki S, Kokotos G. Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases A2. Biochim Biophys Acta Mol Cell Biol Lipids. 2019;1864:941\u201356.","journal-title":"Biochim Biophys Acta Mol Cell Biol Lipids"},{"key":"703_CR14","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1161\/01.ATV.0000280571.28102.d4","volume":"27","author":"S Tsimikas","year":"2007","unstructured":"Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2007;27:2094\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"703_CR15","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1093\/eurheartj\/ehp311","volume":"30","author":"T Munzel","year":"2009","unstructured":"Munzel T, Gori T. Lipoprotein-associated phospholipase A(2), a marker of vascular inflammation and systemic vulnerability. Eur Heart J. 2009;30:2829\u201331.","journal-title":"Eur Heart J"},{"key":"703_CR16","doi-asserted-by":"crossref","unstructured":"Siddiqui MK, Kennedy G, Carr F, Doney ASF, Pearson ER, Morris AD, et al. Lp-PLA2 activity is associated with increased risk of diabetic retinopathy: a longitudinal disease progression study. Diabetologia 2018;61:1344\u201353.","DOI":"10.1007\/s00125-018-4601-7"},{"key":"703_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12944-016-0184-9","volume":"15","author":"Z Li","year":"2016","unstructured":"Li Z, Liu J, Shen Y, Zeng F, Zheng D. Increased Lipoprotein-associated phospholipase A2 activity portends an increased risk of resistant hypertension. Lipids Health Dis. 2016;15:15.","journal-title":"Lipids Health Dis"},{"key":"703_CR18","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","volume":"312","author":"ML O\u2019Donoghue","year":"2014","unstructured":"O\u2019Donoghue ML, Braunwald E, White HD, Lukas MA, Tarka E, Steg PG, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. J Am Med Assoc. 2014;312:1006\u201315.","journal-title":"J Am Med Assoc"},{"key":"703_CR19","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","volume":"370","author":"S Investigators","year":"2014","unstructured":"Investigators S, White HD, Held C, Stewart R, Tarka E, Brown R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014;370:1702\u201311.","journal-title":"N Engl J Med"},{"key":"703_CR20","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1016\/j.bmcl.2013.03.062","volume":"23","author":"K Wang","year":"2013","unstructured":"Wang K, Xu W, Zhang W, Mo M, Wang Y, Shen J. Triazole derivatives: a series of Darapladib analogues as orally active Lp-PLA2 inhibitors. Bioorg Med Chem Lett. 2013;23:2897\u2013901.","journal-title":"Bioorg Med Chem Lett"},{"key":"703_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.trci.2015.06.003","volume":"1","author":"G Maher-Edwards","year":"2015","unstructured":"Maher-Edwards G, De\u2019Ath J, Barnett C, Lavrov A, Lockhart A. A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer\u2019s disease. Alzheimers Dement (N. Y). 2015;1:131\u201340.","journal-title":"Alzheimers Dement (N. Y)"},{"key":"703_CR22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.ophtha.2014.12.014","volume":"122","author":"G Staurenghi","year":"2015","unstructured":"Staurenghi G, Ye L, Magee MH, Danis RP, Wurzelmann J, Adamson P, et al. Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study. Ophthalmology. 2015;122:990\u20136.","journal-title":"Ophthalmology"},{"key":"703_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbadis.2017.10.001","volume":"1864","author":"W Gan","year":"2018","unstructured":"Gan W, Ren J, Li T, Lv S, Li C, Liu Z, et al. The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1\u201310.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"703_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbadis.2017.10.001","volume":"1864","author":"W Gan","year":"2018","unstructured":"Gan W, Ren J, Li T, Lv S, Li C, Liu Z, et al. The SGK1 inhibitor EMD638683, prevents Angiotensin II-induced cardiac inflammation and fibrosis by blocking NLRP3 inflammasome activation. Biochim Biophys Acta. 2018;1864:1\u201310.","journal-title":"Biochim Biophys Acta"},{"key":"703_CR25","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/aps.2011.127","volume":"32","author":"MM Hu","year":"2011","unstructured":"Hu MM, Zhang J, Wang WY, Wu WY, Ma YL, Chen WH, et al. The inhibition of lipoprotein-associated phospholipase A2 exerts beneficial effects against atherosclerosis in LDLR-deficient mice. Acta Pharmacol Sin. 2011;32:1253\u20138.","journal-title":"Acta Pharmacol Sin"},{"key":"703_CR26","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1161\/HYPERTENSIONAHA.113.02604","volume":"64","author":"Y Li","year":"2014","unstructured":"Li Y, Wu Y, Zhang C, Li P, Cui W, Hao J, et al. gammadeltaT Cell-derived interleukin-17A via an interleukin-1beta-dependent mechanism mediates cardiac injury and fibrosis in hypertension. Hypertension. 2014;64:305\u201314.","journal-title":"Hypertension"},{"key":"703_CR27","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1093\/eurheartj\/ehy085","volume":"39","author":"L Wang","year":"2018","unstructured":"Wang L, Zhang YL, Lin QY, Liu Y, Guan XM, Ma XL, et al. CXCL1-CXCR2 axis mediates angiotensin II-induced cardiac hypertrophy and remodelling through regulation of monocyte infiltration. Eur Heart J. 2018;39:1818\u201331.","journal-title":"Eur Heart J"},{"key":"703_CR28","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1016\/j.celrep.2018.08.017","volume":"24","author":"YK Tham","year":"2018","unstructured":"Tham YK, Bernardo BC, Huynh K, Ooi JYY, Gao XM, Kiriazis H, et al. Lipidomic profiles of the heart and circulation in response to exercise versus cardiac pathology: a resource of potential biomarkers and drug targets. Cell Rep. 2018;24:2757\u201372.","journal-title":"Cell Rep"},{"key":"703_CR29","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0008-6363(99)00239-4","volume":"44","author":"T Hayek","year":"1999","unstructured":"Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Breslow JL, et al. The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc Res. 1999;44:579\u201387.","journal-title":"Cardiovasc Res"},{"key":"703_CR30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/cvr\/cvt258","volume":"101","author":"L Wang","year":"2014","unstructured":"Wang L, Li YL, Zhang CC, Cui W, Wang X, Xia Y, et al. Inhibition of Toll-like receptor 2 reduces cardiac fibrosis by attenuating macrophage-mediated inflammation. Cardiovasc Res. 2014;101:383\u201392.","journal-title":"Cardiovasc Res"},{"key":"703_CR31","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.jacc.2011.11.019","volume":"59","author":"JF Ferguson","year":"2012","unstructured":"Ferguson JF, Hinkle CC, Mehta NN, Bagheri R, Derohannessian SL, Shah R, et al. Translational studies of lipoprotein-associated phospholipase A2 in inflammation and atherosclerosis. J Am Coll Cardiol. 2012;59:764\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"703_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nm.3762","volume":"21","author":"HM Kang","year":"2015","unstructured":"Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, et al. Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med. 2015;21:37\u201346.","journal-title":"Nat Med"},{"key":"703_CR33","doi-asserted-by":"publisher","first-page":"e47217","DOI":"10.1371\/journal.pone.0047217","volume":"7","author":"J Liu","year":"2012","unstructured":"Liu J, Ma KL, Gao M, Wang CX, Ni J, Zhang Y, et al. Inflammation disrupts the LDL receptor pathway and accelerates the progression of vascular calcification in ESRD patients. PLoS One. 2012;7:e47217.","journal-title":"PLoS One"},{"key":"703_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.biocel.2015.01.011","volume":"61","author":"J Liu","year":"2015","unstructured":"Liu J, Ma KL, Zhang Y, Wu Y, Hu ZB, Lv LL, et al. Activation of mTORC1 disrupted LDL receptor pathway: a potential new mechanism for the progression of non-alcoholic fatty liver disease. Int J Biochem Cell Biol. 2015;61:8\u201319.","journal-title":"Int J Biochem Cell Biol"},{"key":"703_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2174\/1871525713666150310110934","volume":"12","author":"CG Musso","year":"2015","unstructured":"Musso CG, Alfie J. Resistant hypertension in the elderly-second line treatments: aldosterone antagonists, central alpha-agonist agents, alpha-adrenergic receptor blockers, direct vasodilators, and exogenous nitric oxide donors. Cardiovasc Hematol Agents Med Chem. 2015;12:170\u20133.","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"703_CR36","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1161\/CIRCHEARTFAILURE.115.002334","volume":"8","author":"S He","year":"2015","unstructured":"He S, Chousterman BG, Fenn A, Anzai A, Nairz M, Brandt M, et al. Lp-PLA2 antagonizes left ventricular healing after myocardial infarction by impairing the appearance of reparative macrophages. Circ Heart Fail. 2015;8:980\u20137.","journal-title":"Circ Heart Fail"},{"key":"703_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1164\/ajrccm.156.1.9608084","volume":"156","author":"M Triggiani","year":"1997","unstructured":"Triggiani M, De Marino V, Sofia M, Faraone S, Ambrosio G, Carratu L, et al. Characterization of platelet-activating factor acetylhydrolase in human bronchoalveolar lavage. Am J Respir Crit Care Med. 1997;156:94\u2013100.","journal-title":"Am J Respir Crit Care Med"},{"key":"703_CR38","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jacc.2013.05.105","volume":"63","author":"A Mahmut","year":"2014","unstructured":"Mahmut A, Boulanger MC, El Husseini D, Fournier D, Bouchareb R, Despres JP, et al. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. J Am Coll Cardiol. 2014;63:460\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"703_CR39","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1161\/CIRCULATIONAHA.108.771899","volume":"118","author":"PW Serruys","year":"2008","unstructured":"Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation. 2008;118:1172\u201382.","journal-title":"Circulation"},{"key":"703_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nrd4381","volume":"13","author":"A Mullard","year":"2014","unstructured":"Mullard A. GSK\u2019s darapladib failures dim hopes for anti-inflammatory heart drugs. Nat Rev Drug Discov. 2014;13:481\u20132.","journal-title":"Nat Rev Drug Discov"},{"key":"703_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/med.21597","volume":"40","author":"F Huang","year":"2020","unstructured":"Huang F, Wang K, Shen J. Lipoprotein-associated phospholipase A2: The story continues. Med Res Rev. 2020;40:79\u2013134.","journal-title":"Med Res Rev"},{"key":"703_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2147\/VHRM.S217904","volume":"15","author":"TA Wihastuti","year":"2019","unstructured":"Wihastuti TA, Aini FN, Tjahjono CT, Sulfia YH, Sholichah Z, Heriansyah T. Lp-PLA2 selective inhibitor (Darapladib) effect in lowering the expression level of IL-1B and IL-6 In the renal at type 2 diabetes mellitus. Vasc Health Risk Manag. 2019;15:503\u20138.","journal-title":"Vasc Health Risk Manag"},{"key":"703_CR43","doi-asserted-by":"publisher","first-page":"115133","DOI":"10.1016\/j.taap.2020.115133","volume":"402","author":"YJ Wang","year":"2020","unstructured":"Wang YJ, Chang SB, Wang CY, Huang HT, Tzeng SF. The selective lipoprotein-associated phospholipase A2 inhibitor darapladib triggers irreversible actions on glioma cell apoptosis and mitochondrial dysfunction. Toxicol Appl Pharmacol. 2020;402:115133.","journal-title":"Toxicol Appl Pharmacol"},{"key":"703_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1161\/ATVBAHA.114.303763","volume":"35","author":"F Usui","year":"2015","unstructured":"Usui F, Shirasuna K, Kimura H, Tatsumi K, Kawashima A, Karasawa T, et al. Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm. Arterioscler Thromb Vasc Biol. 2015;35:127\u201336.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"703_CR45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.ebiom.2018.04.022","volume":"31","author":"SY Zhang","year":"2018","unstructured":"Zhang SY, Dong YQ, Wang P, Zhang X, Yan Y, Sun L, et al. Adipocyte-derived lysophosphatidylcholine activates adipocyte and adipose tissue macrophage nod-like receptor protein 3 inflammasomes mediating homocysteine-induced insulin resistance. EBioMedicine. 2018;31:202\u201316.","journal-title":"EBioMedicine"},{"key":"703_CR46","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.3389\/fimmu.2019.02927","volume":"10","author":"R Correa","year":"2019","unstructured":"Correa R, Silva LFF, Ribeiro DJS, Almeida RDN, Santos IO, Correa LH, et al. Lysophosphatidylcholine induces NLRP3 inflammasome-mediated foam cell formation and pyroptosis in human monocytes and endothelial cells. Front Immunol. 2019;10:2927.","journal-title":"Front Immunol"},{"key":"703_CR47","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1084\/jem.20150237","volume":"214","author":"L Freeman","year":"2017","unstructured":"Freeman L, Guo H, David CN, Brickey WJ, Jha S, Ting JP. NLR members NLRC4 and NLRP3 mediate sterile inflammasome activation in microglia and astrocytes. J Exp Med. 2017;214:1351\u201370.","journal-title":"J Exp Med"},{"key":"703_CR48","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/nm.1870","volume":"14","author":"RL Wilensky","year":"2008","unstructured":"Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med. 2008;14:1059\u201366.","journal-title":"Nat Med"},{"key":"703_CR49","doi-asserted-by":"publisher","first-page":"15863","DOI":"10.1021\/bi048825z","volume":"43","author":"S Benitez","year":"2004","unstructured":"Benitez S, Villegas V, Bancells C, Jorba O, Gonzalez-Sastre F, Ordonez-Llanos J, et al. Impaired binding affinity of electronegative low-density lipoprotein (LDL) to the LDL receptor is related to nonesterified fatty acids and lysophosphatidylcholine content. Biochemistry. 2004;43:15863\u201372.","journal-title":"Biochemistry"},{"key":"703_CR50","doi-asserted-by":"publisher","first-page":"e14721","DOI":"10.14814\/phy2.14721","volume":"9","author":"Y Cyr","year":"2021","unstructured":"Cyr Y, Lamantia V, Bissonnette S, Burnette M, Besse-Patin A, Demers A, et al. Lower plasma PCSK9 in normocholesterolemic subjects is associated with upregulated adipose tissue surface-expression of LDLR and CD36 and NLRP3 inflammasome. Physiol Rep. 2021;9:e14721.","journal-title":"Physiol Rep"},{"key":"703_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.7555\/JBR.34.20190124","volume":"34","author":"M Faraj","year":"2020","unstructured":"Faraj M. LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue. J Biomed Res. 2020;34:251\u20139.","journal-title":"J Biomed Res"},{"key":"703_CR52","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357\u201361.","journal-title":"Nature"},{"key":"703_CR53","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.4049\/jimmunol.1102048","volume":"187","author":"P Rider","year":"2011","unstructured":"Rider P, Carmi Y, Guttman O, Braiman A, Cohen I, Voronov E, et al. IL-1alpha and IL-1beta recruit different myeloid cells and promote different stages of sterile inflammation. J Immunol. 2011;187:4835\u201343.","journal-title":"J Immunol"},{"key":"703_CR54","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.4049\/jimmunol.1101737","volume":"189","author":"MD McGeough","year":"2012","unstructured":"McGeough MD, Pena CA, Mueller JL, Pociask DA, Broderick L, Hoffman HM, et al. Cutting edge: IL-6 is a marker of inflammation with no direct role in inflammasome-mediated mouse models. J Immunol. 2012;189:2707\u201311.","journal-title":"J Immunol"},{"key":"703_CR55","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13024-017-0175-y","volume":"12","author":"R Natoli","year":"2017","unstructured":"Natoli R, Fernando N, Madigan M, Chu-Tan JA, Valter K, Provis J, et al. Microglia-derived IL-1beta promotes chemokine expression by Muller cells and RPE in focal retinal degeneration. Mol Neurodegener. 2017;12:31.","journal-title":"Mol Neurodegener"},{"key":"703_CR56","doi-asserted-by":"publisher","first-page":"80","DOI":"10.2174\/1874312901206010080","volume":"6","author":"CM Artlett","year":"2012","unstructured":"Artlett CM. The role of the NLRP3 inflammasome in fibrosis. Open Rheumatol J. 2012;6:80\u20136.","journal-title":"Open Rheumatol J"},{"key":"703_CR57","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1093\/ndt\/gfp208","volume":"24","author":"DD Luo","year":"2009","unstructured":"Luo DD, Fielding C, Phillips A, Fraser D. Interleukin-1 beta regulates proximal tubular cell transforming growth factor beta-1 signalling. Nephrol Dial Transpl. 2009;24:2655\u201365.","journal-title":"Nephrol Dial Transpl"},{"key":"703_CR58","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1161\/CIRCRESAHA.119.315125","volume":"125","author":"MS Stratton","year":"2019","unstructured":"Stratton MS, Bagchi RA, Felisbino MB, Hirsch RA, Smith HE, Riching AS, et al. Dynamic chromatin targeting of BRD4 stimulates cardiac fibroblast activation. Circ Res. 2019;125:662\u201377.","journal-title":"Circ Res"},{"key":"703_CR59","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1093\/cvr\/cvz318","volume":"116","author":"M Wang","year":"2020","unstructured":"Wang M, Qian L, Li J, Ming H, Fang L, Li Y, et al. GHSR deficiency exacerbates cardiac fibrosis: role in macrophage inflammasome activation and myofibroblast differentiation. Cardiovasc Res.\u00a02020;116:2091\u2013102.","journal-title":"Cardiovasc Res"},{"key":"703_CR60","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2017.04.014","volume":"262","author":"S Acosta","year":"2017","unstructured":"Acosta S, Taimour S, Gottsater A, Persson M, Engstrom G, Melander O, et al. Lp-PLA2 activity and mass for prediction of incident abdominal aortic aneurysms: a prospective longitudinal cohort study. Atherosclerosis. 2017;262:14\u20138.","journal-title":"Atherosclerosis"},{"key":"703_CR61","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/cjp2.69","volume":"3","author":"L Lehtinen","year":"2017","unstructured":"Lehtinen L, Vainio P, Wikman H, Huhtala H, Mueller V, Kallioniemi A, et al. PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelial-mesenchymal transition in cultured breast cancer cells. J Pathol Clin Res. 2017;3:123\u201338.","journal-title":"J Pathol Clin Res"},{"key":"703_CR62","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2006.05.001","volume":"191","author":"Y Shi","year":"2007","unstructured":"Shi Y, Zhang P, Zhang L, Osman H, Mohler ER 3rd, Macphee C, et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis. 2007;191:54\u201362.","journal-title":"Atherosclerosis"},{"key":"703_CR63","doi-asserted-by":"publisher","first-page":"e0202797","DOI":"10.1371\/journal.pone.0202797","volume":"13","author":"H Zhang","year":"2018","unstructured":"Zhang H, Zhou W, Cao C, Zhang W, Liu G, Zhang J. Amelioration of atherosclerosis in apolipoprotein E-deficient mice by combined RNA interference of lipoprotein-associated phospholipase A2 and YKL-40. PLoS One. 2018;13:e0202797.","journal-title":"PLoS One"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00703-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00703-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T21:04:21Z","timestamp":1667077461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-021-00703-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1038\/s41401-021-00703-7","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"27 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}